Cephalon expands pact on Celator delivery tech; NanoBioMagnetics wins SBIR grant;

> Cephalon is expanding its research pact with Celator, relying on Celator's nano-encapsulation delivery technology in its cancer drug development programs. Report

> NanoBioMagnetics has been awarded a Phase I Small Business Innovative Research grant from the National Science Foundation to study the effectiveness of magnetically vectored therapeutics in the treatment of locally advanced breast cancers. Release

> Quay Pharma's new purpose-designed laboratories and headquarters, which will focus on new drug delivery technologies as well as other research programs, have been officially opened by the Deputy First Minister of Wales. Release

> Celsion, which is developing oncology drugs using focused heat energy in combination with heat-activated drug delivery systems, has hired Jeffrey W. Church as vice president and CFO. Release

> Lipoxen's patent on its monofunctional PSA PolyXen technology has been extended. Report

And Finally... Researchers working on new devices that can be implanted in the human body to dispense therapeutics may want to learn more about the case of a British researcher whose virus-infected chip implanted in his hand was able to contaminate surrounding systems. Story

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.